NCI requests $7.8B for FY2023 to increase R01 paylines to 13th percentile

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

NCI is asking for an appropriation of $7.8 billion for fiscal year 2023—about $800 million above the House’s FY22 proposed budget for NCI.

This amount, specified by the institute’s Bypass Budget, is calibrated toward raising paylines to the 15th percentile by 2025. 

“Several years ago, we started a concerted effort to raise the payline to the 15th percentile by 2025,” Sharpless said Sept. 1 in his remarks to the National Cancer Advisory Board. “That is the ‘15-by-25’ initiative, and robust and sustained investments are needed to achieve that level.”

As it stands, NCI paylines are at the 11th percentile, and the success rate for investigator-initiated research project grants is 12.8%.

The Bypass Budget, also known as the Professional Judgment Budget, is one of the unique authorities given to NCI under the National Cancer Act of 1971. The law allows the institute director to bypass budget review at NIH and HHS and submit this request directly to the White House. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Matthew Bin Han Ong
Matthew Bin Han Ong
Table of Contents

YOU MAY BE INTERESTED IN

MAIA Biotechnology Inc. and BeiGene entered into a clinical supply agreement to assess the efficacy of THIO, MAIA Biotechnology’s small molecule telomere-targeting anticancer agent, in combination with BeiGene’s immune checkpoint inhibitor tislelizumab, in three cancer indications. The single-arm pivotal phase II trials will study the drug combination in hepatocellular carcinoma, small cell lung cancer, and colorectal cancer.
Matthew Bin Han Ong
Matthew Bin Han Ong

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login